Eli Lilly, Ascidian Sign $1.9 Billion Kidney-Disease Treatment Deal

Lonza NewsStipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila Times

Endpoints NewsParabilis Medicines charts $413M IPO to back peptide pipeline

FierceBiotechInnovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADC

PharmaVoiceHouse bill aims to crack down on China biotech deals

PharmaVoicePharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?

FierceBiotechMedline earns FDA warning letter ire for repeated toxic bacteria problems

FierceBiotechFrom business strategy to CAR-T responses, for Cabaletta it’s all about ‘durability’

BrukerBruker showcases expanded microbiology diagnostics portfolio - Investing.com

BrukerBruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026 - 巴士的報

Endpoints NewsADC Therapeutics' confirmatory data for Zynlonta muddied by death rates

Eli LillyEli Lilly continues genetic medicine push with $1.9bn Ascidian partnership - Pharmaceutical Technology

Eli LillyEli Lilly forms billion-dollar genetic kidney disease partnership with US biotech Ascidian Therapeutics - medwatch.com